Patients with EGFR- or ALK-positive lung cancer whose pretreatment PDC indicates insensitivity to the matched targeted drugs will need more careful monitoring for earlier disease progression; this will enable planning for a possible alternative treatment, such as combination therapy or a modified regimen. This evidence concerns the gene ALK and lung cancer.